[Alpha Biz= Reporter Kim Jisun] Dongwha Pharm announced on the 9th that it has decided to acquire shares in Hironic, a company specializing in aesthetic medical devices. The acquisition deal is valued at 160 billion KRW, with Mirae Asset Venture Investment PE also planning to co-invest. Following the signing of the contract on the 6th, Dongwha Pharm expects to complete the transaction by December after due diligence.
Hironic develops, manufactures, and sells advanced skin care devices based on high-intensity focused ultrasound (HIFU) and radio frequency (RF) technologies. The company offers a global range of products, including both hospital-grade and personal aesthetic devices.
The aesthetic medical device industry, driven by advancements in technology, is creating a new paradigm by replacing traditional plastic surgeries with non-invasive procedures like skin lifting, tightening, and fat reduction. The sector is expected to show strong growth potential in the future.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
